Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 443 participants.

Also called NCT02343926

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 443 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02343926
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02343926. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
GEMIGLIPTIN LS15-0444
Intervention (Drug)
vildagliptin
Intervention (Drug)
metformin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02343926
Content hash
895f36fc3d7a22537159c0428de69ed74ea89ea3d3490a7c04fa232e8f3a07c8